Insiders who bought ImmuCell Corporation (NASDAQ:ICCC) stock in the last 12 months were richly rewarded last week. The company's market value increased by US$11m as a result of the stock's 12% gain over the same period. Put another way, the original US$141.1k acquisition is now worth US$239.9k.
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.
Over the last year, we can see that the biggest insider purchase was by President Paul F. Te Boekhorst for US$76k worth of shares, at about US$9.50 per share. We do like to see buying, but this purchase was made at well below the current price of US$11.42. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.
While ImmuCell insiders bought shares during the last year, they didn't sell. The average buy price was around US$6.72. We don't deny that it is nice to see insiders buying stock in the company. However, you should keep in mind that they bought when the share price was meaningfully below today's levels. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
View our latest analysis for ImmuCell
ImmuCell is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. ImmuCell insiders own about US$27m worth of shares. That equates to 28% of the company. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
The fact that there have been no ImmuCell insider transactions recently certainly doesn't bother us. On a brighter note, the transactions over the last year are encouraging. Insiders own shares in ImmuCell and we see no evidence to suggest they are worried about the future. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. You'd be interested to know, that we found 3 warning signs for ImmuCell and we suggest you have a look.
But note: ImmuCell may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.